Toutes les études
RecrutementPHASE2INTERVENTIONNEL

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

This study, called a Phase 2 trial, is looking at a new medicine called Anumigilimab for adults living with sickle cell disease. The main goal is to check how safe Anumigilimab is when given under the skin. Some participants will receive the active medicine, while others will get a placebo (a dummy medicine without any active ingredients). This helps researchers understand the medicine's true effects. The study will last for 64 weeks, which is about 15 months. During this time, the dose of Anumigilimab will be slowly increased to find the best tolerated amount, and then participants will continue on that dose. This research is important for finding new ways to manage sickle cell disease.

En un coup d'œil

Statut
Recrutement
Phase
PHASE2
Sponsor
CSL Behring
Objectif d'inscription
63
Démarrer
02 Feb 2026
Achèvement estimé
15 Aug 2028

De quoi parle cette étude ?

This study is a Phase 2 trial, which means it's an early but important step in developing new medicines. For adults with sickle cell disease, researchers are looking at a new drug called Anumigilimab. The main purpose of this study is to carefully check if Anumigilimab is safe for people with sickle cell disease. It's designed to be a thorough investigation into any potential side effects.

Participants will be given the study medicine, or a placebo (an inactive substance that looks just like the study medicine), as an injection under the skin. This approach helps researchers to accurately compare the effects of the new medicine against no active treatment, without anyone knowing who is receiving which, until the study is over. The study will last for a total of 64 weeks, which is a bit over a year. During the first 12 weeks, the dose of the medicine will be gradually increased to find the highest amount that each person can comfortably take. After this, participants will continue on that dose for the remaining 52 weeks.

Finding new, safe, and effective treatments for sickle cell disease is really important for improving the lives of those affected. Studies like this help us understand if new medicines could be a good option for the future. By carefully observing participants and gathering information on how they respond to Anumigilimab, researchers hope to learn more about its potential role in managing sickle cell disease.

Points clés

  • This study is testing a new medicine called Anumigilimab for sickle cell disease.
  • The main goal is to check how safe the medicine is.
  • Participants will receive the medicine or a placebo as an injection under the skin.
  • The study lasts for 64 weeks (about 15 months).
  • It's for adults aged 18 and over with sickle cell disease who have experienced pain crises.
  • This research is an important step in finding new treatments for sickle cell disease.

Qui peut être éligible ?

To join this study, you need to be an adult, aged 18 or older, and have a confirmed diagnosis of sickle cell disease, no matter your specific type. You should also have experienced a certain number of pain crises (called VOCs) in the past year that required medical help and strong pain relief.

You might be taking a medicine called Hydroxyurea (HU) – if so, you need to have been on a stable dose for at least a month. If you've stopped taking HU, or if it wasn't right for you, you might still be able to join. Your doctor will check if you meet all the health requirements to ensure the study is safe for you.

There are also a few reasons why someone might not be able to join. For example, if your white blood cell count (a type of blood cell) is too low, or if you've recently changed your dose of other sickle cell preventive medicines, you might not be eligible. These rules are in place to keep everyone safe and make sure the study results are clear.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Do you have a confirmed diagnosis of sickle cell disease?
  3. Have you had 1 to 12 pain crises (VOCs) that needed medical help in the last year?
  4. Are you on a stable dose of Hydroxyurea for at least 30 days, or have you stopped/refused it?
  5. Do you have a healthy enough white blood cell count (neutrophils)?
  6. Have you been on a stable dose of any other sickle cell preventive medicines for at least 30 days?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you will be in it for a total of 64 weeks, which is about 15 months. For the first 12 weeks, you'll have regular visits where the dose of the study medicine will be slowly increased to find the best amount for you. After that, you'll continue on that dose for the remaining 52 weeks.

Throughout the study, you'll receive the medicine (either Anumigilimab or a placebo) as an injection under your skin. You'll have regular check-ups with the study team. These visits will involve various tests and assessments, such as blood tests, to monitor your health and see how you are responding to the treatment. The research team will explain the full schedule of visits and what each visit will involve in detail.

Risques et avantages potentiels

Participating in a clinical trial offers potential benefits, such as gaining access to a new treatment before it's widely available and contributing to medical research that could help others with sickle cell disease in the future. However, there are also potential risks, including side effects from the study medicine, which may not yet be fully known. You might also receive a placebo, meaning you won't get the active medicine. The research team will explain all known risks and discomforts involved. Remember, joining is entirely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (38)

  • UAMS Medical Center
    Code postal vérifié
    Little Rock, États-Unis· Recrutement
  • University of California Irvine
    Code postal vérifié
    Orange, United States· Recrutement
  • The Foundation for Sickle Cell Disease
    Code postal vérifié
    Hollywood, États-Unis· Recrutement
  • Arthur M. Blank Hospital- Children's Healthcare of Atlanta
    Code postal vérifié
    Atlanta, États-Unis· Recrutement
  • Center for Cancer and Blood Disorders
    Code postal vérifié
    Bethesda, United States· Recrutement
  • Boston Medical Center
    Code postal vérifié
    Boston, États-Unis· Recrutement
  • University of Minnesota
    Code postal vérifié
    Minneapolis, États-Unis· Recrutement
  • Southern Specialty Research
    Code postal vérifié
    Flowood, United States· Recrutement
  • NYC Health + Hospitals/Queens
    Code postal vérifié
    Jamaica, United States· Recrutement
  • Columbia University Medical Center
    Code postal vérifié
    New York, États-Unis· Recrutement
  • Jacobi Medical Center
    Code postal vérifié
    Le Bronx, États-Unis· Recrutement
  • Ohio State University
    Code postal vérifié
    Columbus, États-Unis· Recrutement

Questions fréquentes

What is Anumigilimab?

Anumigilimab is an investigational medicine being studied for sickle cell disease. It's not yet approved for general use.

Qu'est-ce qu'un 'placebo' ?

A placebo is a dummy medicine that looks exactly like the real medicine but contains no active ingredients. It helps researchers compare the effects of the new drug.

Why is this called a 'Phase 2' study?

Phase 2 studies are an early stage of research focusing on finding the right dose and further checking the safety of a new medicine in a larger group of people.

Will I know if I'm getting the actual medicine or the placebo?

No, this is a 'double-blind' study, meaning neither you nor your study doctor will know whether you're receiving Anumigilimab or the placebo until the study ends.

Comment le médicament sera-t-il administré ?

The study medicine will be given as an injection under the skin.

Comment en savoir plus

Trial Registration Coordinator

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Safety of Anumigilimab (CSL324) in Adults With Sickle Cell D… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.